Advertisement

Management of Type 2 Diabetes in Youth: An Update

  Related Editorial

  Patient Information Handout

ACF  This article exemplifies the AAFP 2007 Annual Clinical Focus on management of chronic illness.

Although type 1 diabetes historically has been more common in patients eight to 19 years of age, type 2 diabetes is emerging as an important disease in this group. Type 2 diabetes accounts for 8 to 45 percent of new childhood diabetes. This article is an update from the National Diabetes Education Program on the management of type 2 diabetes in youth. High-risk youths older than 10 years have a body mass index greater than the 85th percentile for age and sex plus two additional risk factors (i.e., family history, high-risk ethnicity, acanthosis nigricans, polycystic ovary syndrome, hypertension, or dyslipidemia). Reducing overweight and impaired glucose tolerance with increased physical activity and healthier eating habits may help prevent or delay the development of type 2 diabetes in high-risk youths. The American Academy of Pediatrics does not recommend population-based screening of high-risk youths; however, physicians should closely monitor these patients because early diagnosis may be beneficial. The American Diabetes Association recommends screening high-risk youths every two years with a fasting plasma glucose test. Patients diagnosed with diabetes should receive self-management education, behavior interventions to promote healthy eating and physical activity, appropriate therapy for hyperglycemia (usually metformin and insulin), and treatment of comorbidities. (Am Fam Physician 2007;76:658–64, 665–6. Copyright © 2007 American Academy of Family Physicians.)

More than 13,000 youths are diagnosed with diabetes every year, making it one of the most common chronic childhood diseases in the United States.13 The prevalence of childhood type 2 diabetes has increased by 33 percent in the past 15 years,3 mirroring the increasing rates of overweight in this population.4 In response to this emerging problem, the American Diabetes Association (ADA) developed a consensus statement in 2000 to guide primary care physicians on the prevention, screening, and treatment of type 2 diabetes in youth.5 In 2003, the ADA developed an additional consensus guideline for the management of dyslipidemia,6 and the American Heart Association developed a guideline on the primary prevention of atherosclerotic cardiovascular disease in youth.7

Diagnosis

Glucose intolerance is part of a continuum that ranges from normal blood glucose levels to clinically evident type 2 diabetes. Children at risk of type 2 diabetes often are overweight and insulin resistant. Together, these metabolic risk factors substantially increase the risk of atherosclerosis.8,9

The U.S. Preventive Services Task Force (USPSTF) concludes that there is insufficient evidence to recommend for or against routine screening for overweight in youth to prevent adverse health outcomes10; however, American Academy of Family Physicians policy states that “optimal weight management in children and adolescents is desirable. The effectiveness of screening and counseling for overweight is uncertain.”11 The American Academy of Pediatrics endorses universal screening using body mass index (BMI) and growth curves to identify overweight children (i.e., those with a BMI greater than the 95th percentile for sex and age).12 Clinical growth charts are available at http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/clinical_charts.htm.

Table 1 presents ADA recommendations for diabetes screening in youth.5,13 The USPSTF has not addressed screening youths for diabetes.5,14

Distinguishing between type 1 and 2 diabetes can be difficult in a child or adolescent with new-onset diabetes. Youths with type 1 diabetes often have antibodies against islet cell antigens (i.e., glutamic acid decarboxylase or insulin autoantibodies), whereas children with type 2 diabetes are overweight and usually do not have autoantibodies. The clinical distinction between the types of diabetes can be blurred because ketosis may be present in patients with type 2 diabetes, and patients with type 1 diabetes may be overweight and have acanthosis nigricans.13,15

Insulin and C-peptide levels are usually low at diagnosis in patients with either type of diabetes; furthermore, some patients have elements of both types. Youths with insulin resistance, overweight, and type 2 diabetes may have the pancreatic islet cell antibodies that are typically associated with type 1 diabetes; this is sometimes called “hybrid,” “mixed,” or “double” diabetes. If the diagnosis is unclear, it may be helpful to measure islet cell antibodies and C-peptide levels one year or more after the diagnosis.

Table 1
ADA Guidelines for Screening Youths for Type 2 Diabetes

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Treatment

The treatment of children and adolescents with type 2 diabetes differs from that of adults because treatment in youths is focused on decreased insulin sensitivity with advancing sexual maturity, physical growth, ability to provide self-management, and neurologic vulnerability to hypoglycemia (in children younger than five years).13 The diabetes management regimen should be individualized to the patient.13 Table 2 includes resources for more information about the treatment of youths with type 2 diabetes.

Diabetes care is best provided by a team that includes the patient and family and should address medical, educational, nutritional, and behavioral issues. Education about healthy eating, daily physical activity, insulin and medication administration, and self-monitoring of blood glucose levels is essential. Families should be encouraged to share with team members their concerns about day-to-day management tasks.

METABOLIC CONTROL

Diet and exercise alone are effective for metabolic control in less than 10 percent of youths with type 2 diabetes, and an oral medication or insulin is usually required.3 Metformin (Glucophage) is an oral medication approved for use in some children. Because metformin's onset of action is delayed about four weeks, patients with substantial ketosis, ketoacidosis, or markedly elevated blood glucose levels initially should be treated with insulin. Metformin may be added after blood glucose levels are controlled and symptoms subside.16 The insulin may be tapered to discontinuation if metabolic control is maintained.

Basal-bolus therapy using a combination of long- or intermediate-acting and short-acting insulin provides flexibility and can improve A1C levels. Insulin pumps can provide even greater flexibility, but they cost more and require more education for accurate use. Fixed-dose regimens provide little flexibility and may not fit the lifestyle of adolescents. A preprandial insulin bolus is based on an insulin:carbohydrate ratio, and an insulin-correction dose should be administered for hyperglycemia. Further adjustment of insulin or food intake may be needed in anticipation of special circumstances such as increased exercise. Patients should self-monitor their blood glucose level before meals and at bedtime.

Table 2
Resources for More Information About Managing Diabetes in Youth

American Association of Diabetes Educators

Web site: http://www.aadenet.org

Telephone: 800-338-3633

American Diabetes Association

Web site: http://www.diabetes.org

Telephone: 800-342-2383

American Dietetic Association

Web site: http://www.eatright.org

Telephone: 800-877-1600

American Heart Association

Web site: http://www.americanheart.org

Telephone: 800-242-8721

CDC Division of Diabetes Translation

Web site: http://www.cdc.gov/diabetes/

Telephone: 800-232-4636

CDC growth charts

Web site: http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/clinical_charts.htm

Juvenile Diabetes Research Foundation International

Web site: http://www.jdrf.org

Telephone: 800-533-2873

National Diabetes Education Program

Web site: http://www.ndep.nih.gov/diabetes/youth/youth.htm

Telephone: 800-438-5383

National Institute of Diabetes and Digestive and Kidney Diseases

Web site: http://diabetes.niddk.nih.gov/

Telephone: 800-860-8747


CDC = Centers for Disease Control and Prevention.

Treatment regimens (e.g., blood glucose goals, frequency of self-monitoring, type of insulin, dose and frequency of insulin administration, use of injections or a pump, nutritional management, physical activity levels) vary among patients. The diabetes care team should determine the regimen that best suits the patient's individual characteristics and circumstances.

Table 3
Optimal Plasma Glucose and A1C Goals for Youths with Type 1 Diabetes

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Because a safe lower-than-normal range for blood glucose has not been identified, the ADA recommends that blood glucose levels be maintained as close to the normal range as possible without serious hypoglycemia.5  The ADA provides blood glucose goals only for young persons with type 1 diabetes (Table 313,17); however, because vascular damage may be mediated by glycated end products, it appears reasonable to use these goals in the management of type 2 diabetes.

BODY WEIGHT MANAGEMENT

The increase in overweight in youths has been associated with increased consumption of beverages with a high sugar content,18 long hours watching television,19 and reduced physical activity.20 Children with a BMI greater than the 85th percentile for age and sex should be counseled to increase physical activity and reduce weight gain while allowing for normal growth and development.21  Table 4 includes recommendations for managing body weight in youths with or at risk of type 2 diabetes.22

Health Maintenance Schedule

Diabetes presents distinctive issues for youths (e.g., emotional and behavioral challenges, self-management and adherence considerations). Table 5 summarizes a consensus-based management schedule for monitoring diabetes and comorbidities in youths with diabetes.5,13,17

Performing diabetes management tasks can make school-age youths, particularly adolescents, feel different from their classmates. Learning to cope with the disease may lead to depression or an eating disorder. A social worker or psychologist can help patients and their families adjust to lifestyle changes and can provide resources for health education; financial, social, and mental health services; transportation; and home visits.

It is important that parents talk to their children about avoiding tobacco, alcohol, and drug use. Smoking and diabetes independently increase the risk of cardiovascular disease, and persons with diabetes who smoke have a greatly increased risk of heart disease and circulatory problems. Binge drinking can be associated with acute hyperglycemia or severe hypoglycemia. Because intoxication symptoms are similar to those of hypoglycemia, treatment of hypoglycemia may be delayed in patients who are intoxicated.

Youths should self-manage their diabetes to the extent that is appropriate for their age and maturity level. By six or seven years of age, most children can recognize symptoms of hypoglycemia, perform blood glucose measurements, administer insulin injections, and participate in nutritional decisions. However, children should be supervised until they are able to accurately perform diabetes management tasks independently (e.g., measuring an insulin dose).

Adolescents usually have the motor and cognitive skills to perform all diabetes-related tasks, including determining insulin doses based on blood glucose levels and food intake. Adolescence, however, is a time when peer acceptance is important and risk-taking behaviors and rebellion are common. Thus, diabetes management should be supervised in adolescents, and gradual independence should be allowed based on adherence to the regimen and reasonable metabolic control. During midadolescence, the diabetes care team should stress the importance of checking blood glucose levels before driving to avoid hypoglycemia while driving.

Accommodations may be needed to manage diabetes at school (e.g., in the classroom, during physical education, field trips, and after-school activities). A written plan outlining the student's diabetes management tasks is helpful. A guide for effective diabetes management at school is available at http://www.ndep.nih.gov/diabetes/youth/youth.htm.

Reducing Cardiovascular Disease Risk

Diabetes microvascular complications and cardiovascular risk factors, including dyslipidemia and hypertension, have been observed among teenage Pima Indians2 and in other youths in the United States and may be present at diabetes diagnosis.23,24 Monitoring for hypertension and early treatment can slow the progression of retinopathy, nephropathy, and possibly neuropathy that can occur in adulthood.25 Evidence indicates that primary prevention of cardiovascular disease should begin in childhood.7  Table 6 presents consensus-based recommendations for monitoring lipid levels and blood pressure in youths.7,13

Table 6
Recommendations for Monitoring Blood Pressure and Lipid Levels in Youth

Blood pressure7

Hypertension is defined as an average systolic or diastolic blood pressure greater than the 95th percentile for age, sex, and height measured on at least three separate days

Normal blood pressure levels for age, sex, and height; appropriate methods for measurement; and treatment recommendations are available at www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf

Angiotensin-converting enzyme inhibitors are preferred in children with microalbuminuria

Lipids13

Optimal levels are: LDL cholesterol less than 100 mg per dL (2.60 mmol per L); high-density lipoprotein cholesterol greater than 35 mg per dL (0.90 mmol per L); and triglycerides less than 150 mg per dL (1.70 mmol per L)

A lipid profile should be obtained at diagnosis, after glucose control is established; if lipids are at optimal levels, repeat lipid profile every three to five years

If the LDL cholesterol level is greater than 100 mg per dL, prescribe an exercise plan and healthy diet; if goals are not reached after six months of diet and exercise, consider statin* therapy for patients with an LDL cholesterol level of 130 to 159 mg per dL (3.35 to 4.10 mmol per L), and begin medications for patients with an LDL cholesterol level of 160 mg per dL (4.15 mmol per L) or greater

Weight loss, increased physical activity, and improved glycemic control often lead to improved lipid levels


Further Study

There are ongoing studies of youths with diabetes. The HEALTHY study (part of STOPP-T2D [Studies to Treat or Prevent Pediatric Type 2 Diabetes]) will help determine effective ways to lower diabetes risk factors in middle school students. The SEARCH for Diabetes in Youth project is tracking the incidence and prevalence of diabetes in the United States and will help clarify trends in childhood and adolescent diabetes. For more information on the project, go to http://www.searchfordiabetes.org/. The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study seeks to identify the best treatment for children and adolescents with type 2 diabetes. For more information on the study, go to http://www.niddk.nih.gov/patient/today/today.htm.


The Authors

KEVIN PETERSON, MD, MPH, FAAFP, chairs the National Diabetes Education Program's Health Care Provider Work Group. He is an associate professor in the Department of Family Medicine and Community Health at the University of Minnesota Medical School, Minneapolis. Dr. Peterson received his medical degree from Mayo Medical School, Rochester, Minn., and completed a family medicine residency at the University of Minnesota Medical School.

JANET SILVERSTEIN, MD, chairs the National Diabetes Education Program's Children's Work Group. She is a professor in the Department of Pediatrics and is chief of the department's Division of Endocrinology at the University of Florida College of Medicine, Gainesville. Dr. Silverstein received her medical degree from the University of Pennsylvania School of Medicine, Philadelphia, and completed a pediatric residency at Children's Hospital of Philadelphia.

FRANCINE KAUFMAN, MD, chairs the National Diabetes Education Program's diabetes prevention initiative for women with a history of gestational diabetes and is vice chair of the program's Children's Work Group. She is head of the Center for Endocrinology, Diabetes and Metabolism at Childrens Hospital Los Angeles (Calif.) and is a professor of pediatrics at the Keck School of Medicine of the University of Southern California, Los Angeles. Dr. Kaufman received her medical degree from Chicago (Ill.) Medical School at Rosalind Franklin University of Medicine and Science and completed a pediatric residency at Childrens Hospital Los Angeles.

ELIZABETH WARREN-BOULTON, RN, MSN, is a senior writer for Hager Sharp, a health communications firm in Washington, D.C., that provides support for the National Diabetes Education Program. She received her master's degree in nursing from St. Louis (Mo.) University School of Nursing.

Address correspondence to Kevin Peterson, MD, MPH, University of Minnesota, Dept. of Family Medicine and Community Health, 925 Delaware St. SE, Suite 220, Minneapolis, MN 55455 (e-mail: peter223@umn.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Centers for Disease Control and Prevention. National diabetes fact sheet. General information and national estimates on diabetes in the United States, 2005. Accessed April 2, 2007, at: http://www.cdc.gov/diabetes/pubs/factsheet05.htm.

2. Fagot-Campagna  A, Pettitt  DJ, Engelgau  MM, Burrows  NR, Geiss  LS, Valdez  R, et al.  Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective.  J Pediatr.  2000;136:664–72.

3. Kaufman  FR.  Type 2 diabetes mellitus in children and youth: a new epidemic.  J Pediatr Endocrinol Metab.  2002;15(suppl 2):737–44.

4. Ogden  CL, Carroll  MD, Curtin  LR, McDowell  MA, Tabak  CJ, Flegal  KM.  Prevalence of overweight and obesity in the United States, 1999–2004.  JAMA.  2006;295:1549–55.

5. American Diabetes Association.  Type 2 diabetes in children and adolescents.  Diabetes Care.  2000;23:381–9.

6. American Diabetes Association.  Management of dyslipidemia in children and adolescents with diabetes.  Diabetes Care.  2003;26:2194–7.

7. McCrindle  BW, Urbina  EM, Dennison  BA, Jacobson  MS, Steinberger  J, Rocchini  AP, et al.  Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.  Circulation.  2007;115:1948–67.

8. Weiss  R, Dziura  J, Burgert  TS, Tamborlane  WV, Taksali  SE, Yeckel  CW, et al.  Obesity and the metabolic syndrome in children and adolescents.  N Engl J Med.  2004;350:2362–74.

9. Molnar  D.  The prevalence of the metabolic syndrome and type 2 diabetes mellitus in children and adolescents.  Int J Obes Relat Metab Disord.  2004;28(suppl 3):S70–4.

10. Whitlock  EP, Williams  SB, Gold  R, Smith  PR, Shipman  SA.  Screening and interventions for childhood over-weight: a summary of evidence for the U.S. Preventive Services Task Force.  Pediatrics.  2005;116:e125–44.

11. American Academy of Family Physicians. Recommendations for clinical preventive services. Obesity. Accessed May 15, 2007, at: http://www.aafp.org/online/en/home/clinical/exam/k-o.html.

12. Moyer  VA, Klein  JD, Ockene  JK, Teutsch  SM, Johnson  MS, Allan  JD.  Screening for overweight in children and adolescents: where is the evidence? A commentary by the Childhood Obesity Working Group of the U.S. Preventive Services Task Force.  Pediatrics.  2005;116:235–8.

13. American Diabetes Association.  Standards of medical care in diabetes—2006 [Published correction appears in Diabetes Care 2006;29:1192].  Diabetes Care.  2006;29(suppl 1):S4–42.

14. Gahagan  S, Silverstein  J, for the American Academy of Pediatrics Committee on Native American Child Health and Section on Endocrinology.  Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children.  Pediatrics.  2003;112:e328.

15. Weiss  R, Taksali  SE, Tamborlane  WV, Burgert  TS, Savoye  M, Caprio  S.  Predictors of changes in glucose tolerance status in obese youth.  Diabetes Care.  2005;28:902–9.

16. Zuhri-Yafi  MI, Brosnan  PG, Hardin  DS.  Treatment of type 2 diabetes mellitus in children and adolescents.  J Pediatr Endocrinol Metab.  2002;15(suppl 1):541–6.

17. Silverstein  J, Klingensmith  G, Copeland  K, Plotnick  L, Kaufman  F, Laffel  L, et al.  Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.  Diabetes Care.  2005;28:186–212.

18. Ludwig  DS, Peterson  KE, Gortmaker  SL.  Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis.  Lancet.  2001;357:505–8.

19. Robinson  TN.  Television viewing and childhood obesity.  Pediatr Clin North Am.  2001;48:1017–25.

20. Kimm  SY, Glynn  NW, Kriska  AM, Barton  BA, Kronsberg  SS, Daniels  SR, et al.  Decline in physical activity in black girls and white girls during adolescence.  N Engl J Med.  2002;347:709–15.

21. U.S. Department of Health and Human Services. U.S. Department of Agriculture. Nutrition and your health: dietary guidelines for Americans. Accessed April 2, 2007, at: http://www.health.gov/dietaryguidelines/dga2005/report/.

22. United States Department of Agriculture. Dietary guidelines for Americans 2005. Accessed May 14, 2007, at: http://www.healthierus.gov/dietaryguidelines/.

23. Deckelbaum  RJ, Williams  CL.  Childhood obesity: the health issue.  Obes Res.  2001;9(suppl 4):239S–43S.

24. Crawford  PB, Story  M, Wang  MC, Ritchie  LD, Sabry  ZI.  Ethnic issues in the epidemiology of childhood obesity.  Pediatr Clin North Am.  2001;48:855–78.

25. UK Prospective Diabetes Study Group.  Tight blood pressure control and risk of macrovascular and micro-vascular complications in type 2 diabetes: UKPDS 38 [Published correction appears in BMJ 1999;318:29].  BMJ.  1998;317:703–13.

Advertisement